MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2019
The development of Medivir's clinical portfolio is progressing according to planJuly – SeptemberFinancial summary · Net turnover amounted to SEK 1.7 (3.0) million. · The loss before interest, tax, depreciation and amortization (EBITDA) totaled SEK -22.0 (-66,9) million. Basic and diluted earnings per share amounted to SEK -0.95 (-2.93) SEK and SEK -0.95(-2.93) respectively. · Cash flow from operating activities amounted to SEK -31.8 (-78.4) million. · Liquid assets and short-term investments totaled SEK 158.5 (357.1) million at the period end. January – September